Navigation Links
Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
Date:3/11/2008

continues to pursue

development of SNS-595 in acute myeloid leukemia (AML). A Phase 1b

clinical trial of SNS-595 in combination with cytarabine in relapsed

or refractory AML patients is in progress. Sunesis plans to begin

enrollment in a Phase 2 clinical trial of SNS-595 on a weekly dose

schedule in previously untreated elderly AML patients in the first

half of 2008. Sunesis expects to report data later this year for

both AML clinical trials.

-- Results from a non-clinical study of SNS-032, a potent and selective

inhibitor of cyclin-dependent kinases (CDKs) 2, 7 and 9, were presented

at ASH. These data demonstrated that SNS-032 induces apoptosis in

chronic lymphocytic leukemia (CLL) cells. Furthermore, SNS-032's in

vitro activity compared favorably with flavopiridol in CLL cells

obtained from patients. SNS-032 currently is in a Phase 1 clinical

trial of patients with relapsed or refractory CLL or multiple myeloma.

To date, the drug has been well tolerated in this trial, and dose

escalation in both indications is expected to be completed this year.

-- Sunesis is continuing enrollment in its Phase 1 dose-escalating trial

of SNS-314, a potent and selective inhibitor of Aurora kinases A, B and

C, in advanced solid tumors. To date, SNS-314 has been well tolerated

and no dose-limiting toxicities have been observed. The company

expects to identify a maximum-tolerated dose in this Phase 1 clinical

trial this year.

-- In December, Sunesis and the Multiple Myeloma Research Consortium

(MMRC) announced a collaboration to evaluate the preclinical activity

of SNS-032 in multiple myeloma-relevant models and in primary disease

tissue, extending non-clinical studies performed by Sunesis.

-- In February 2008, Sunesis received
'/>"/>

SOURCE Sunesis Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Sunesis Pharmaceuticals to Present Interim Phase 2 Data for SNS-595 at the 39th Annual Meeting on Womens Cancer
2. Sunesis Pharmaceuticals Announces Milestone Payment from Inflammation Collaboration
3. Sunesis Pharmaceuticals Appoints Lesley A. Stolz, Ph.D., Vice President, Corporate and Business Development
4. Sunesis Pharmaceuticals to Report Third Quarter 2007 Financial Results
5. Sunesis Pharmaceuticals to Present Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
6. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
7. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
8. Alseres Pharmaceuticals Presents Inosine and Dopamine Transporter (DAT) Blocker Preclinical Data at the American Society for Experimental NeuroTherapeutics (ASENT) Conference
9. Keryx Biopharmaceuticals Announces that SUN-MICRO Phase 3 Clinical Trial Fails to Meet Primary Efficacy Endpoint
10. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results and Clinical Program Overview on March 12, 2008
11. Jazz Pharmaceuticals, Inc. Announces Webcast of March 13 Investor Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... (PRWEB) October 22, 2014 Physicians ... its cardiovascular pharmacogenetics menu, which enables healthcare providers ... With PCLS’s evidence-based results, healthcare providers are ... optimize their therapy, while minimizing risks for adverse ... U.S., according to the FDA [1] more than ...
(Date:10/22/2014)... VANCOUVER , Oct. 22, 2014 /PRNewswire/ - iCo ... ICOTF), today announced next steps for its Oral ... findings from its in vitro work ... therapy.  iCo now plans to complete pre clinical ... an initial Phase 1A clinical trial, utilizing approximately ...
(Date:10/22/2014)... and HONG KONG , Oct. ... disease therapeutics enterprise, announced today that rare disease expert ... as vice president, research. Dr. McKew brings more than ... leadership positions at the National Institutes of Health, Wyeth ... by Wyeth). Dr. McKew will lead aTyr,s efforts to expand ...
(Date:10/20/2014)... October 20, 2014 Convey Computer ... a team from Iowa State University won first place ... Using a Convey HC-2ex, the team’s solution achieved the ... faster than the second place finisher. , Experts from ... upon the month long challenge, using a variety of ...
Breaking Biology Technology:PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 2PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 3iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 2iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 3aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 2Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 3
... Phosphatase useful for dephosphorylation serine,threonine or tyrosine ... Mary Ellen Simcox ,Stratagene Cloning Systems, Inc. ... dualspecificity protein,phosphatase that has been produced as ... calmodulinbinding peptide. The tag simplifies purification of ...
... polymerase delivers high fidelity and great,performance ... Holly Hogrefe ,Stratagene , Stratagene has ... novel enzyme formulation that provides,superior performance in ... that Herculase enhanced DNA polymerase is even ...
... Generate cDNA libraries with as little as 50 ng ... Tanya Hosfield ,Marie Callahan ,John C. Bauer Mike ... Lenhart Paul Young ,Human Genome Sciences, Rockville, Maryland , ... new method to generate high-efficiency cDNA libraries in a plasmid,vector. ...
Cached Biology Technology:Highly Active and Removable AffinityTagged Lambda Phosphatase 2Highly Active and Removable AffinityTagged Lambda Phosphatase 3Highly Active and Removable AffinityTagged Lambda Phosphatase 4Unique DNA Polymerase Formulation Excels in a Broad Range of PCR,Applications 2Unique DNA Polymerase Formulation Excels in a Broad Range of PCR,Applications 3Unique DNA Polymerase Formulation Excels in a Broad Range of PCR,Applications 4Unique DNA Polymerase Formulation Excels in a Broad Range of PCR,Applications 5Unique DNA Polymerase Formulation Excels in a Broad Range of PCR,Applications 6Unique DNA Polymerase Formulation Excels in a Broad Range of PCR,Applications 7Unique DNA Polymerase Formulation Excels in a Broad Range of PCR,Applications 8Unique DNA Polymerase Formulation Excels in a Broad Range of PCR,Applications 9Unique DNA Polymerase Formulation Excels in a Broad Range of PCR,Applications 10Constructing Directional cDNA Libraries from Limited Amounts of RNA 2Constructing Directional cDNA Libraries from Limited Amounts of RNA 3Constructing Directional cDNA Libraries from Limited Amounts of RNA 4Constructing Directional cDNA Libraries from Limited Amounts of RNA 5Constructing Directional cDNA Libraries from Limited Amounts of RNA 6Constructing Directional cDNA Libraries from Limited Amounts of RNA 7
(Date:10/18/2014)... 2,000 patients referred for evaluation of suspected genetic ... for 25 percent, including detection of a number ... to disease, according to a study appearing in ... to coincide with the American Society of Human ... exons or coding regions of thousands of genes ...
(Date:10/17/2014)... knowledge regarding Ebola is critical and pertinent for practicing ... global outbreak and epidemic. The Journal, Disaster Medicine ... issue, Ebola Virus and Public Health, to surround the ... this critical societal moment. , On October 17, ... Clinicians . The primer was prepared by Dr. Eric ...
(Date:10/17/2014)... of Copenhagen have shown for the first time how ... fibrosis patients, giving them the opportunity to get tremendous ... , The study also discovered the bacterial growth in ... halted or slowed down by the immune cells. The ... and helped "suffocate" the bacteria, forcing the bacteria to ...
Breaking Biology News(10 mins):Whole-exome sequencing shows potential as diagnostic tool 2Scientists opens black box on bacterial growth in cystic fibrosis lung infection 2
... MADISON, WI, MARCH 1, 2011 Methane ... permafrost, termites, oceans, freshwater bodies, non-wetland soils, are all ... methane presence ca n be accredited to human-related activities. ... burning, waste management and animal husbandry. The release of ...
... available in Spanish . , Those who ... and teas may tend to overlook the benefits of drinking ... Agricultural Research magazine, the idea that herbal teas may provide ... U.S. Department of Agriculture (USDA)-funded scientists in Boston, Mass., ...
... release is available in Spanish . ... (UPV/EHU), has developed genetic-molecular tools, with the intention of completing ... equine breeds in the Basque Country Autonomous Community (CAPVEAE) and ... DNA sequence) and certain SNPs (a kind of variation in ...
Cached Biology News:Measuring methane 2Don't underestimate the power of herbal teas 2Basque thesis investigates wide diversity within certain ovine, bovine and equine breeds 2Basque thesis investigates wide diversity within certain ovine, bovine and equine breeds 3
MOUSE ANTI HUMAN NPM...
MOUSE ANTI PROTEIN KINASE C BETA 2 Immunogen: Protein kinase C beta 2...
Antibodies were affinity purified using epitopes specific to JLP immobilized on solid support....
... et.al. (1997) • Contains short ... biochemistry & molecular biology, arranged ... Entries give details of biochemical ... which they are involved and ...
Biology Products: